Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in Idiopathic Membranous Glomerulonephropathy
NCT01610492Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2012
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belimumab in membranous glomerulonephritis (MGN), sponsored by GSK. Primary endpoints: Change From Baseline in Proteinuria Levels at 28 weeks and Change From Baseline in Anti-phospholipase A2 Receptor (PLA2R) Autoantibody Titers at 28 weeks. Started Jul 2012; status: completed.
02
Drugs
belimumab
03
Conditions
membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on NCT01610492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01610492.